Combined therapy with immune-suppressive drug in children with immunoglobulin resistant Kawasaki disease
Not Applicable
- Conditions
- Kawasaki disease
- Registration Number
- JPRN-UMIN000032096
- Lead Sponsor
- Dokkyo medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Not provided
Exclusion Criteria
shock or oversensitivity of asprin, immunoglobulin, infliximab, and cyclosporin A. low contraction at left ventricle (FS<0.28) low renal function (creatinine <0.9mg/dl or estimated GFR<50ml/min/1.73m2) Contraindication of infliximab and cyclosporin A. Liver dysfunction (AST or ALT >500 U/L) before continuos infusion of cyclosporin A. Critical active bacterial infection before therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of coronary artery dilatation until 1 month.
- Secondary Outcome Measures
Name Time Method Evaluation of side effect with combined therapy. Evaluation of alternation of expression levels of RNA.